Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

10.35USD
28 Mar 2017
Change (% chg)

-- (--)
Prev Close
$10.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
425,413
52-wk High
$11.71
52-wk Low
$3.91

Latest Key Developments (Source: Significant Developments)

Progenics Pharmaceuticals posts Q4 loss per share $0.10
Thursday, 9 Mar 2017 07:30am EST 

Progenics Pharmaceuticals Inc : Progenics Pharmaceuticals announces fourth quarter and full-year 2016 financial results and business update .Q4 loss per share $0.10.  Full Article

Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment
Tuesday, 14 Feb 2017 07:00am EST 

Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals announces initiation of a phase 1 clinical trial of its PSMA-targeted therapeutic candidate 1095 for the treatment of metastatic prostate cancer.  Full Article

Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald
Monday, 9 Jan 2017 06:06am EST 

Progenics Pharmaceuticals Inc :Entered controlled equity offering sales agreement with Cantor Fitzgerald, pursuant to which Co may offer, sell up to $75 million stock.  Full Article

Progenics Pharma says 190 of 450 patients enrolled in phase 3 SPECT/CT imaging agent trial
Thursday, 22 Dec 2016 04:15pm EST 

Progenics Pharmaceuticals Inc : Progenics Pharmaceuticals Inc says approximately 190 of a planned 450 patients have been enrolled in trial to date . Progenics Pharmaceuticals announces independent committee’s positive recommendation for continuation of phase 3 clinical trial of SPECT/CT imaging agent 1404 .Progenics Pharmaceuticals announces independent committee’s positive recommendation for continuation of phase 3 clinical trial of SPECT/CT imaging agent 1404.  Full Article

Progenics Pharmaceuticals Q2 loss per share $0.08
Thursday, 4 Aug 2016 07:30am EDT 

Progenics Pharmaceuticals Inc : Q2 loss per share $0.08 . Progenics Pharmaceuticals announces second quarter 2016 financial and business results . Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S .On track to initiate phase 2/3 trial for PYL(TM) imaging agent and phase 1 trial for 1095 this year.  Full Article

Valeant and Progenics announce FDA approvals for relistor
Tuesday, 19 Jul 2016 06:04pm EDT 

Progenics Pharmaceuticals Inc : Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016 . Valeant and Progenics announce FDA approves relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain .FDA has approved relistor (methylnaltrexone bromide) tablets for treatment of opioid-induced constipation.  Full Article

Progenics Pharmaceuticals signs commercial license agreement with Selexis SA
Tuesday, 21 Jun 2016 08:45am EDT 

Press Release : Under agreement, progenics will have use of Selexis CHO-M cell line and sure technology platform . Financial terms were not disclosed .Progenics Pharmaceuticals, Inc. Signs commercial license agreement with Selexis SA for use of proprietary cell line and suretechnology platform.  Full Article

Progenics Pharmaceuticals Inc announces the appointment of Patrick Fabbio as CFO
Monday, 16 Nov 2015 07:30am EST 

Progenics Pharmaceuticals Inc:Says appointment of Patrick Fabbio as Chief Financial Officer.  Full Article

Progenics Pharmaceuticals makes tender offer for in Exini Diagnostics
Tuesday, 13 Oct 2015 02:29am EDT 

Exini Diagnostics AB:Progenics Pharmaceuticals Inc has on Oct 13 announced offer to tender all of shares in Exini for a consideration of 3.15 Swedish crowns per share.Says total value, based on 18,381,081 issued shares in Exini, amounts to about 57.9 million Swedish crowns.Offer price represents a premium of about 93 percent compared with EXINI's closing price of 1.63 crows per share on NASDAQ First North Stockholm on Oct. 12.Board decided to unanimously recommend that shareholders accept offer.  Full Article

Valeant Pharmaceuticals International Inc and Progenics Pharmaceuticals Inc announce FDA acceptance of NDA submission for oral RELISTOR
Tuesday, 8 Sep 2015 08:00am EDT 

Valeant Pharmaceuticals International Inc and Progenics Pharmaceuticals Inc:Says that U.S. Food and Drug Administration (FDA) has accepted for review Valeant's New Drug Application for RELISTOR (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.Says FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of April 16, 2016.  Full Article

More From Around the Web

BRIEF-Progenics Pharmaceuticals posts Q4 loss per share $0.10

* Progenics Pharmaceuticals announces fourth quarter and full-year 2016 financial results and business update